tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CH:BSLN Stock Latest News

Basilea Achieves Sales Milestone with Cresemba in Europe
Company AnnouncementsBasilea Achieves Sales Milestone with Cresemba in Europe
15h ago
Basilea Secures BARDA Funding for Novel Antibiotic Development
PremiumCompany Announcements
Basilea Secures BARDA Funding for Novel Antibiotic Development
1M ago
Basilea Pharmaceutica’s Strategic Expansion and Financial Backing Earns Buy Rating
PremiumRatings
Basilea Pharmaceutica’s Strategic Expansion and Financial Backing Earns Buy Rating
1M ago
Basilea Secures Additional BARDA Funding for Antifungal Development
PremiumCompany Announcements
Basilea Secures Additional BARDA Funding for Antifungal Development
2M ago
Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
PremiumCompany Announcements
Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
2M ago
BSLN
Basilea Pharmaceutica’s Earnings Call Highlights Growth and Challenges
PremiumCompany AnnouncementsBasilea Pharmaceutica’s Earnings Call Highlights Growth and Challenges
2M ago
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
Premium
Company Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
2M ago
BSLN
Basilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 2025
Premium
Company Announcements
Basilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 2025
3M ago
PremiumCompany Announcements
Basilea Pharmaceutica’s Phase 3 Trial: A Potential Game-Changer in Antifungal Treatment
3M ago
Basilea Pharmaceutica Expands Pipeline with New Antibiotic License
PremiumCompany Announcements
Basilea Pharmaceutica Expands Pipeline with New Antibiotic License
3M ago
PremiumCompany Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatments
3M ago
PremiumCompany Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer for Mold Infections
3M ago
PremiumCompany AnnouncementsBasilea Pharmaceutica Completes Phase 1 Study of Fosmanogepix: Implications for Investors
3M ago
Premium
Company Announcements
Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer for Mold Infections
3M ago
Basilea Pharmaceutica’s Promising Future: Buy Rating Backed by Fosmanogepix Potential and Robust Valuation
Premium
Ratings
Basilea Pharmaceutica’s Promising Future: Buy Rating Backed by Fosmanogepix Potential and Robust Valuation
3M ago
PremiumCompany Announcements
Basilea Pharmaceutica’s Fosmanogepix Study: A Potential Game-Changer in Antifungal Treatment
3M ago
PremiumCompany Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatments
3M ago
PremiumCompany Announcements
Basilea Pharmaceutica’s Fosmanogepix: A New Hope for Drug-Resistant Fungal Infections
3M ago
PremiumCompany Announcements
Basilea Pharmaceutica’s Phase 3 Trial: A Potential Game-Changer in Antifungal Treatment
4M ago
PremiumCompany AnnouncementsBasilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
4M ago
Basilea Pharmaceutica Receives Buy Rating Backed by U.S. Government Funding and Promising Drug Developments
Premium
Ratings
Basilea Pharmaceutica Receives Buy Rating Backed by U.S. Government Funding and Promising Drug Developments
4M ago
Basilea Secures $39 Million BARDA Funding for Antifungal Drug Development
Premium
Company Announcements
Basilea Secures $39 Million BARDA Funding for Antifungal Drug Development
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >